183 related articles for article (PubMed ID: 21610124)
1. Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial.
Vehik K; Cuthbertson D; Ruhlig H; Schatz DA; Peakman M; Krischer JP;
Diabetes Care; 2011 Jul; 34(7):1585-90. PubMed ID: 21610124
[TBL] [Abstract][Full Text] [Related]
2. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.
Skyler JS; Krischer JP; Wolfsdorf J; Cowie C; Palmer JP; Greenbaum C; Cuthbertson D; Rafkin-Mervis LE; Chase HP; Leschek E
Diabetes Care; 2005 May; 28(5):1068-76. PubMed ID: 15855569
[TBL] [Abstract][Full Text] [Related]
3. Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.
; Krischer JP; Schatz DA; Bundy B; Skyler JS; Greenbaum CJ
JAMA; 2017 Nov; 318(19):1891-1902. PubMed ID: 29164254
[TBL] [Abstract][Full Text] [Related]
4. Effect of oral insulin on insulin autoantibody levels in the Diabetes Prevention Trial Type 1 oral insulin study.
Barker JM; McFann KK; Orban T
Diabetologia; 2007 Aug; 50(8):1603-6. PubMed ID: 17583798
[TBL] [Abstract][Full Text] [Related]
5. Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol.
Ziegler AG; Achenbach P; Berner R; Casteels K; Danne T; Gündert M; Hasford J; Hoffmann VS; Kordonouri O; Lange K; Elding Larsson H; Lundgren M; Snape MD; Szypowska A; Todd JA; Bonifacio E;
BMJ Open; 2019 Jun; 9(6):e028578. PubMed ID: 31256036
[TBL] [Abstract][Full Text] [Related]
6. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?
Schatz D; Cuthbertson D; Atkinson M; Salzler MC; Winter W; Muir A; Silverstein J; Cook R; Maclaren N; She JX; Greenbaum C; Krischer J
Pediatr Diabetes; 2004 Jun; 5(2):72-9. PubMed ID: 15189492
[TBL] [Abstract][Full Text] [Related]
7. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial.
Füchtenbusch M; Rabl W; Grassl B; Bachmann W; Standl E; Ziegler AG
Diabetologia; 1998 May; 41(5):536-41. PubMed ID: 9628270
[TBL] [Abstract][Full Text] [Related]
8. Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset.
Triolo TM; Chase HP; Barker JM;
Diabetes Care; 2009 May; 32(5):769-73. PubMed ID: 19407074
[TBL] [Abstract][Full Text] [Related]
9. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial.
Bonifacio E; Ziegler AG; Klingensmith G; Schober E; Bingley PJ; Rottenkolber M; Theil A; Eugster A; Puff R; Peplow C; Buettner F; Lange K; Hasford J; Achenbach P;
JAMA; 2015 Apr; 313(15):1541-9. PubMed ID: 25898052
[TBL] [Abstract][Full Text] [Related]
10. The Effect of DPT-1 Intravenous Insulin Infusion and Daily Subcutaneous Insulin on Endogenous Insulin Secretion and Postprandial Glucose Tolerance.
Hao W; Greenbaum CJ; Krischer JP; Cuthbertson D; Marks JB; Palmer JP
Diabetes Care; 2015 May; 38(5):891-6. PubMed ID: 25720600
[TBL] [Abstract][Full Text] [Related]
11. Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes.
Ergun-Longmire B; Marker J; Zeidler A; Rapaport R; Raskin P; Bode B; Schatz D; Vargas A; Rogers D; Schwartz S; Malone J; Krischer J; Maclaren NK
Ann N Y Acad Sci; 2004 Dec; 1029():260-77. PubMed ID: 15681764
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus.
Ceglia L; Lau J; Pittas AG
Ann Intern Med; 2006 Nov; 145(9):665-75. PubMed ID: 17088580
[TBL] [Abstract][Full Text] [Related]
13. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.
Chaillous L; Lefèvre H; Thivolet C; Boitard C; Lahlou N; Atlan-Gepner C; Bouhanick B; Mogenet A; Nicolino M; Carel JC; Lecomte P; Maréchaud R; Bougnères P; Charbonnel B; Saï P
Lancet; 2000 Aug; 356(9229):545-9. PubMed ID: 10950231
[TBL] [Abstract][Full Text] [Related]
14. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial.
Hamilton J; Cummings E; Zdravkovic V; Finegood D; Daneman D
Diabetes Care; 2003 Jan; 26(1):138-43. PubMed ID: 12502670
[TBL] [Abstract][Full Text] [Related]
15. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial.
Lind M; Polonsky W; Hirsch IB; Heise T; Bolinder J; Dahlqvist S; Schwarz E; Ólafsdóttir AF; Frid A; Wedel H; Ahlén E; Nyström T; Hellman J
JAMA; 2017 Jan; 317(4):379-387. PubMed ID: 28118454
[TBL] [Abstract][Full Text] [Related]
16. Oral Glucose Tolerance Test Measures of First-phase Insulin Response and Their Predictive Ability for Type 1 Diabetes.
Baidal DA; Warnock M; Xu P; Geyer S; Marks JB; Moran A; Sosenko J; Evans-Molina C
J Clin Endocrinol Metab; 2022 Jul; 107(8):e3273-e3280. PubMed ID: 35524749
[TBL] [Abstract][Full Text] [Related]
17. Expression of GAD65 and islet cell antibody (ICA512) autoantibodies among cytoplasmic ICA+ relatives is associated with eligibility for the Diabetes Prevention Trial-Type 1.
Yu L; Cuthbertson DD; Maclaren N; Jackson R; Palmer JP; Orban T; Eisenbarth GS; Krischer JP;
Diabetes; 2001 Aug; 50(8):1735-40. PubMed ID: 11473032
[TBL] [Abstract][Full Text] [Related]
18. Baseline heterogeneity in glucose metabolism marks the risk for type 1 diabetes and complicates secondary prevention.
Elding Larsson H; Larsson C; Lernmark Å;
Acta Diabetol; 2015 Jun; 52(3):473-81. PubMed ID: 25381193
[TBL] [Abstract][Full Text] [Related]
19. Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?
Fouts A; Pyle L; Yu L; Miao D; Michels A; Krischer J; Sosenko J; Gottlieb P; Steck AK;
Diabetes Care; 2016 Oct; 39(10):1738-44. PubMed ID: 27456836
[TBL] [Abstract][Full Text] [Related]
20. Cytokine profile and insulin antibody IgG subclasses in patients with recent onset type 1 diabetes treated with oral insulin.
Monetini L; Cavallo MG; Sarugeri E; Sentinelli F; Stefanini L; Bosi E; Thorpe R; Pozzilli P;
Diabetologia; 2004 Oct; 47(10):1795-802. PubMed ID: 15502927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
